Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00509002 · FLOW

Participant flow

Iressa Study in Patients With Salivary Gland Cancer · Source last updated 2017-11-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Gefitinib 250 mg daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
    id
    FG000
    title
    Gefitinib
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        37
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        37
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Recruitment Period: May 2004 to October 2006. All recruitment done at The University of Texas MD Anderson Cancer Center.
Complete source fields
groups
  1. description
    Gefitinib 250 mg daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
    id
    FG000
    title
    Gefitinib
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        37
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        37
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Recruitment Period: May 2004 to October 2006. All recruitment done at The University of Texas MD Anderson Cancer Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice